Literature DB >> 10742385

The role of HIV-related chemokine receptors and chemokines in human erythropoiesis in vitro.

M Majka1, J Ratajczak, B Lee, M Honczarenko, R Douglas, M A Kowalska, L Silberstein, A M Gewirtz, M Z Ratajczak.   

Abstract

In order to better define the role of HIV-related chemokines in human erythropoiesis we studied: A) the expression of chemokine receptors, both on human CD34(+) cells which include erythroid progenitors and on more mature erythroid cells; B) the functionality of these receptors by calcium flux, chemotaxis assay and phosphorylation of mitogen-activated protein kinases (MAPK) p42/44 (ERK1/ERK2) and AKT, and finally C) the influence of chemokines on BFU-E formation. We found that HIV-related chemokine receptor CXCR4, but not CCR5, is detectable on human CD34(+) BFU-E cells. CXCR4 surface expression decreased during erythroid maturation, although CXCR4 mRNA was still present in cells isolated from differentiated erythroid colonies. SDF-1, a CXCR4 ligand, induced calcium flux and phosphorylation of MAPK (p42/44) and AKT in CD34(+)KIT(+) bone marrow mononuclear cells which contain BFU-E, as well as chemotactic activity of both human CD34(+) BFU-E progenitors and erythroid cells isolated from day 2-6 BFU-E colonies. Responsiveness to SDF-1 decreased when the cells differentiated to the point of surface expression of the erythroid-specific marker Glycophorin-A. In contrast, the CCR5 ligands (macrophage inflammatory protein-1alpha [MIP-1alpha], MIP-1beta, and RANTES) did not activate calcium flux, MAPK and AKT phosphorylation or chemotaxis of CD34(+)KIT(+) cells or cells isolated from the BFU-E colonies. Interestingly, none of the chemokines tested in this study had any effect on BFU-E colony formation. In conclusion, only CXCR4 is functional, and its specific ligand SDF-1 may therefore play an important role in the homing and/or retention of early erythroid precursors in the bone marrow environment.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10742385     DOI: 10.1634/stemcells.18-2-128

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  6 in total

1.  Conditional inactivation of the CXCR4 receptor in osteoprecursors reduces postnatal bone formation due to impaired osteoblast development.

Authors:  Wei Zhu; Gang Liang; Zhiping Huang; Stephen B Doty; Adele L Boskey
Journal:  J Biol Chem       Date:  2011-06-02       Impact factor: 5.157

2.  Stromal derived factor-1 regulates bone morphogenetic protein 2-induced osteogenic differentiation of primary mesenchymal stem cells.

Authors:  Naobumi Hosogane; Zhiping Huang; Bernard A Rawlins; Xia Liu; Oheneba Boachie-Adjei; Adele L Boskey; Wei Zhu
Journal:  Int J Biochem Cell Biol       Date:  2010-03-31       Impact factor: 5.085

3.  Platelet factor 4 is a negative autocrine in vivo regulator of megakaryopoiesis: clinical and therapeutic implications.

Authors:  Michele P Lambert; Lubica Rauova; Matthew Bailey; Martha C Sola-Visner; M Anna Kowalska; Mortimer Poncz
Journal:  Blood       Date:  2007-05-10       Impact factor: 22.113

4.  Levels of macrophage inflammatory protein 1 alpha (MIP-1 alpha) and MIP-1 beta in intervillous blood plasma samples from women with placental malaria and human immunodeficiency virus infection.

Authors:  Sujittra Chaisavaneeyakorn; Julie M Moore; Lisa Mirel; Caroline Othoro; Juliana Otieno; Sansanee C Chaiyaroj; Ya Ping Shi; Bernard L Nahlen; Altaf A Lal; Venkatachalam Udhayakumar
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

Review 5.  Chemokine receptor CXCR4 as a therapeutic target for neuroectodermal tumors.

Authors:  Hyunsuk Shim; Shinya Oishi; Nobutaka Fujii
Journal:  Semin Cancer Biol       Date:  2008-11-25       Impact factor: 15.707

6.  Severe anaemia is not associated with HIV-1 env gene characteristics in Malawian children.

Authors:  Job C J Calis; Hellen P Rotteveel; Antoinette C van der Kuyl; Fokla Zorgdrager; David Kachala; Michaël Boele van Hensbroek; Marion Cornelissen
Journal:  BMC Infect Dis       Date:  2008-02-29       Impact factor: 3.090

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.